Polymeric nanocarriers are promising entities for cancer diagnosis and therapy. The aim of such nanocarriers is to selectively accumulate in cancerous tissue that is difficult to visualize or treat. The passive accumulation of a nanocarrier in a tumor through extravasation is often attributed to the enhanced permeation and retention (EPR) effect and the size and shape of the nanocarrier. However, the tumor microenvironment is very heterogeneous and the intratumoral pressure is usually high, leading to different opinions about how the EPR of nanocarriers through the irregular vasculature of a tumor leads to accumulation. In order to investigate this topic, we studied methods for the determination of pharmacokinetic parameters, biodistribution and the tumor uptake of nanocarriers. HPGs were determined and increased from 9.9 AE 2.9 to 47.8 AE 7.9 hours with increasing polymer MW.
Introduction
Quantitative SPECT/CT (qSPECT/CT) imaging is a non-invasive technique used to study the distribution and accumulation of radiolabeled nanomedicines in vivo. The visualization of radiopharmaceuticals in the body is benecial for diagnostic and therapeutic applications in cancer research. Due to advances in corrections for photon attenuation and scatter and improved reconstruction algorithms, amongst others, quantitative SPECT data can be produced in units of activity concentration (e.g., kBq mL characteristics and pharmacokinetics. Factors that are reportedly associated to the success of a nanomedicine are size and shape, 2, 3 because they will affect blood circulation, half-life/clearance and tumor accumulation. Although some dependencies are known, these factors have a difficult and not fully understood relationship.
The reported impact of nanomaterial size on extravasation and retention in tumors has been inconsistent in the literature. Any nanomaterials sized above a hydrodynamic diameter of 5.5 nm are able to escape renal clearance 4 and sizes between 30 and 200 nm are presumably desired for intratumoral accumulation. 5 At the lower end of this range, particles can diffuse deep into the tumor, but will not be retained for more than 24 hours, while at the larger end, particles likely reach the extravascular space, but are not able to penetrate further into the tumor. 6 These explanations might be an oversimplication, and it has been reported that successful nanocarriers likely need to be adjusted for each tumor type, because the tumor microenvironment is heterogeneous and might even vary over time and course of treatment. 7 At sizes below 20 nm, nanomaterials are oen described by their MW in kilo Dalton (kDa). Larger MW nanomaterials reportedly accumulate more in the tumor than smaller MWs, 8 which is the key motivation for using nanomaterials instead of just small molecule cancer drugs alone.
Accumulation of a nanomaterial in a tumor by the enhanced permeation and retention (EPR) effect is linked to its increased circulation half-life. The longer the material circulates, the more oen it passes by the tumor with a chance at each pass to penetrate into the tumor and being accumulated. However, increasing the circulation time can also increase toxicity and accumulation in other tissues. The three major challenges in the design of nanomaterials for therapeutic and diagnostic applications have been named by Choi et al. 9 First, the high background uptake by the mononuclear phagocyte system (MPS) in spleen and liver, second, the lack of complete elimination and associated toxicities, and third, achieving a small hydrodynamic diameter (e.g., 5.5 nm) that allows for a rapid equilibration between intra-and extravascular space. 9 If the extravascular space is the tumor, several characteristics must be considered. The endothelium of tumor blood vessels can have fenestrations between 100 and 780 nm and allow nanocarriers to extravasate, but tumor heterogeneity, extracellular matrix and increased interstitial pressure can counterbalance the effect of nanocarrier retention. 10, 11 In fact, passive tumor accumulation of nanocarriers by EPR does not oen work in humans.
12 Only a few tumors (Kaposi sarcoma, tumors of head and neck) have shown EPR in the clinic. The heterogeneity of fenestrations in tumor endothelium, the heterogenous pericyte coverage, variable basement membrane characteristics and extracellular matrix have been identied as some of the major problems.
12 A recent review on nanoparticle delivery into solid tumors reports that the median percentage of administered nanoparticles delivered to the tumor might be as low as 0.7%. 13 Nonetheless, specic design considerations for tumor accumulation appear frequently in the literature, 7, 9, 14 and some already focus on methods to improve or even bypass the EPR effect. 15 This "dark side" of the EPR and ways to mitigate it have been addressed in a recent article by Huynh et al. 15 Several strategies are proposed for enhanced permeation and delivery including the enzymatic in situ formation of nanoparticles in tumors and the use of microbubbles and ultrasound.
The tumor microenvironment is difficult to categorize and the positive aspects of EPR might be overrated or translate poorly into the clinic. Here, we introduce another piece of evidence that relating a specic nanomaterial characteristic (e.g., size or MW) to tumor accumulation might be problematic and depend on the time of measurement. Furthermore, we describe the advantages of quantitative SPECT imaging for nanomaterial distribution studies.
We used the polymer hyperbranched polyglycerol (HPG) as a model nanomaterial tagged with the gamma emitter 67 Ga and studied size-dependent circulation half-life, biodistribution and time-dependent tumor accumulation. We selected this model nanocarrier, because HPGs are stable macromolecules that can be easily synthesized in a one pot reaction and have a narrow size distribution. [16] [17] [18] HPGs have been used in a number of biomedical and tissue engineering applications including drug delivery and scaffolding applications. [19] [20] [21] [22] [23] They are biocompatible, highly water soluble macromolecules, [24] [25] [26] and several biodegradable versions of HPG have recently been prepared.
27-30 HPG's three dimensional structure offers many possibilities to modulate their physicochemical and biological properties. A number of modi-cations are possible on their terminal hydroxyl groups and an introduction of hybrid modications using nanoparticles, carbon nanotubes or quantum dots were recently reported. 31 In addition, these polybranched structures have been used for SPECT imaging aer binding 67 Ga or 111 In, and Gd(III) for magnetic resonance imaging (MRI). [32] [33] [34] In this study the HPGs were modied with a strong chelator for 67 Ga called desferrioxamine (DFO) to be visualized and quantied using SPECT/CT.
Experimental

Materials
Chemicals and reagents were purchased from Sigma-Aldrich Canada Ltd. (Oakville, ON) and used without further purica-tion unless specied. Glycidol (96%) was distilled under reduced pressure and stored at 4 C before use. HPGs were synthesized using Schiff-base chemistry as previously described. 35 HPGs of different MWs (25, 50, 100, 200, 300 and 500 kDa) were created by an anionic ring-opening multi-branching polymerization of glycidol by a single step synthesis. 17, 36, 37 DFO was covalently conjugated to the HPGs using a previously published method.
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Characterization of DFO-HPG. Absorbance spectra were recorded on a Varian (Cary 400 series) UV-vis spectrophotometer and the nanocarriers characterized as to the number of DFO molecules per HPG using the same instrument. 35 The absolute MW of the DFO-HPGs and hydrodynamic size were determined by gel permeation chromatography (GPC) using a DAW HELEOS II multi angle laser light scattering (MALLS) detector (Wyatt Technology Inc.), an Optilab T-rEX refractive index detector and a quasi-elastic light scattering (QELS) detector (Wyatt Technology Inc. CA) in 1.0 N NaNO 3 (pH 8) aqueous solution by following the protocols described previously.
Radiolabeling of DFO-HPG. All DFO-HPGs were radiolabeled as follows: 67 GaCl 3 (185 MBq, 5-10 mL in 0.1 N HCl) was added to DFO-HPG (2.5 mg) in an NH 4 OAc solution (100 mL, 0.1 M). The reaction mixture was stirred at room temperature for 1 h (600 rpm).
67 Ga-DFO-HPGs were puried using centrifugal lters Radioactive intensities on the ITLC were integrated and
.
Mouse model
The current study was performed in accordance with the Animal Care Committee of the University of British Columbia under the approved protocol A12-0172. Six groups of 4 immunodecient female Rag2m mice (homozygous mutation leading to a de-ciency of mature B or T lymphocytes) 38 bearing HER-2 (+) JIMT-1 tumors of 3 to 5 mm diameter 39 on their back were obtained from the BC Cancer Research Centre. Mice (aged 6 to 10 weeks) had been inoculated subcutaneously with 4 Â 10 6 tumour cells suspended in Matrigel® (1 : 1) above the ank unilaterally and tumours grew for 4 weeks before mice were used for the experiment. Mice were anesthetized using isourane on a precision vaporizer (5% in oxygen for induction, between 1.5 and 2.5% in oxygen for maintenance) and received a subcutaneous injection of lactated Ringer's solution (0.5 mL) for hydration prior to each imaging scan. Aer the induction of anesthesia, an injection of 150 mL of 67
Ga-DFO-HPG in PBS was administered via the tail vein. The average injected activity was 565 mCi. Immediately aer injection, the animal was prepared for SPECT/CT imaging on a preclinical small animal scanner. Respiratory rate and temperature were monitored constantly during the scans, and isourane and bed temperature adjusted accordingly. Animals were recovered aer each scan and sacriced following the nal scan 8 days post-injection. Blood was collected by cardiac puncture and a full biodistribution performed.
SPECT/CT parameters and image reconstruction
Dynamic whole-body images were acquired during 40 min using a multimodal SPECT/CT scanner (VECTor/CT, MILabs, The Netherlands) equipped with a UHR-RM 1 mm pinhole collimator. 40 20 frames of 2 min were acquired for the 40 min scan. Thereaer, acquisitions were done at 24, 96 and 192 h postradiotracer injection using a single frame of 40 min. Following each SPECT acquisition, a whole-body CT scan was acquired to obtain anatomical information and both images were registered. The 67 Ga photopeak window was centered at 96 keV with a 20% energy window width and two 10% wide scatter windows were applied on each side to implement scatter correction methods.
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For quantitative analysis, SPECT data were reconstructed with pixel ordered subsets expectations maximization logarithm (P-OSEM) 42 using 10 iterations of 16 subsets and an isotropic 0.4 mm voxel grid. The images were decay corrected to the start scan time and aer CT registration, attenuation correction was applied. For visual representation, the reconstructed volumes of SPECT scans were post-ltered with a 3D Gaussian lter. In order to relate the scanner units (counts/voxel) to radioactivity concentration, a calibration factor was determined scanning a source with a known concentration of 67 Ga.
Quantitative volume of interest (VOI) analysis and calculation of standardized uptake values (SUVs)
Volumes of interest (VOIs) were manually dened (p.mod, VIEW, Version 3.6) to determine the time activity pattern per target organ. Thus, the delineated regions were inside the heart, liver, lung, kidney, bladder and tumor. The average organ activity per volume was obtained from the SPECT images and the Standardized Uptake Value (SUVs) was extracted from each organ using the following formula.
The whole body VOI to measure the total body activity was an oblong sphere enclosing the whole mouse body. The background activity was measured using a 0.47 mL VOI outside the mouse body.
Biodistribution
A full biodistribution was routinely conducted (blood, heart muscle, liver, kidneys, lungs, small intestine, brain, bladder, muscle, spleen, stomach, bone, tumor, and pancreas) aer the last scan on day 8 (192 h). Organs were cleaned from blood, weighed and the activity determined using a g-counter (Packard Cobra II auto-gamma counter, Perkin Elmer, Waltham, MA, USA). The calibration factor for 37 kBq of 67 Ga was 1 524 228 cpm (instrument specic). High activity organs (blood, liver) were measured in an Atomlab 500 dose calibrator (Biodex, Shirley, NY, US) if the activity exceeded 37 kBq. Total organ weights were used for the calculations of injected dose per organ (% ID per g organ) except for blood, liver, muscle, bone and pancreas, where average literature values were used.
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Pharmacokinetic analysis
To determine the half-lives of the different 67 Ga-DFO-HPGs, the activities inside the heart and the whole body activities quantied from the SPECT images were used. For the 100, 200, 300, and 500 kDa nanocarriers all 16 data points (n ¼ 4, 4 timepoint samples) were used. For the 25 and 50 kDa nanocarriers only the rst three time-points (n ¼ 4, 3 time-point samples) were used. The last time-point (day 8) was excluded because the activity was very close (<2 times) to the measured background activity. The data was tted to a one or twocompartmental model using the population PK model object of the pharmacokinetic soware Phoenix WinNonlin 6.3
(Certara, Princeton, NJ, USA). Initial estimates of the primary PK parameters volume of distribution and rate constants were generated using the optical interface of the soware. This interface displays the plots of the dependent variable (activity concentration) vs. time according to the parameters of the model. The naive-pooled data approach (NPD) was used to estimate primary PK parameters for the six 67 Ga-DFO-HPGs.
Mahmood et al. have shown that even sparse data sets (e.g., n ¼ 5, 1 time-point sample) can result in reasonably accurate population estimates of PK parameters using the NPD approach. 46 Standard errors and coefficients of variation (% CV) were estimated by the soware based on the Hessian method of parameter uncertainty. The half-lives were calculated from the primary PK parameter k (terminal elimination rate constant) using t 1/2 ¼ ln(2)/k.
Statistical analysis
Data is expressed as mean and standard deviation unless stated otherwise. Signicance of the experimental data was assessed using a one-way analysis of variance (ANOVA). The signicance level was set to 0.05.
Results and discussion
Synthesis and characterization of the model SPECT/CT nanomaterials
The model SPECT/CT nanomaterials of different MWs and varying number of DFO were synthesized as per our earlier report 35 and characterized using techniques summarized in Table 1 . For simplicity the MWs are approximated in this paper and used as 25, 50, 100, 200, 300, 500 kDa. Furthermore, we designed the polymers such that there is on average the same number of chelating DFO groups per mg of polymer (last column of Table 1 ).
Labeling efficiency and in vitro stability of 67 Ga-DFO-HPGs
The resultant DFO-HPG nanomaterials varied in properties depending on their MW and DFO motifs within the polymer scaffold. The nanocarriers with higher MWs (100-500 kDa) showed greater resistance to transchelation when challenged with either transferrin or EDTA compared to those with lower MWs (25 and 50 kDa) as seen in Table 2 . 
Long-term in vitro stability of 67 Ga-DFO-HPGs in mouse plasma
67 Ga-DFO-HPGs were stored in mouse plasma over 8 days. The presence of free gallium was very low over 8 days and the corresponding stabilities are given in % in Table 3 .
Quantitative volume of interest (VOI) analysis and calculation of standardized uptake values (SUVs)
Organ activities were quantied from the acquired SPECT/CT images (Fig. 1) . The images were clear and the identication of relevant organs was achieved using the co-registered CT image as a guide. Activity concentration data was expressed as standardized uptake values (SUVs) for inside the heart (blood), tumor, liver, lungs, kidney and bladder (Fig. 2) . The tumor time-activity data conrms that all DFO-HPG nanocarriers show accumulation in the tumor reaching a maximal concentration at day 4. The well perfused organs heart (blood), liver, lungs and kidneys showed initially high activities but decreased rapidly thereaer. This corroborates the characteristics of a blood pool imaging agent and non-targeted passive organ delivery. Activity differences are most pronounced between the two smaller HPGs (25, 50 kDa) and the three large HPGs (200, 300, 500 kDa), whereas the 100 kDa HPG shows mixed characteristics. The activity curves for the higher MWs (200, 300, 500 kDa) are very close in maximum activity concentration detected and curve shape. The smaller MWs (25, 50, 100 kDa) show an overall lower concentration and uptake but similar curve progressions, except for the bladder. As expected, the 25 and 50 kDa HPGs show rapid and high bladder uptake within the rst 40 min ($80 and 100 g mL
À1
). The 100 kDa HPG also shows high activity in the bladder initially ($20 g mL
), but otherwise behaves very similar to the three larger MW HPGs (200, 300, 500 kDa) in the quantied organs.
Furthermore, we have determined the tumor-to-blood standardized uptake ratio (SUR)
49 through a dynamic analysis over 8 days. This value can give an indication of the partitioning of the different HPGs between tumor and blood over time (Fig. 3) . It is of particular interest to compare the time it takes to reach a ratio of 1 for each group. The time points are marked in red in Fig. 3 and it is apparent that the time to equilibrium increases with increasing molecular weight from about 1.5 days for the 25 kDa HPG to 7 days for the 500 kDa HPG. In fact, a plot of the equilibrium time from Fig. 3 vs. the MW indicates a linear relationship with an R-squared (R 2 ) statistic of 0.90. A change in SUR curve progression or slope can either result from a change in blood concentration or tumor concentration. We would like to demonstrate this in detail in Fig. 4 , using the 200 kDa DFO-HPG as an example. The disappearance of HPG from the blood and its accumulation in the tumor is shown, and it is apparent that the time to equilibrium is around 4.3 days. While the SPECT results show dynamic tumor uptake over multiple days (Fig. 2B) , the biodistribution data informs about the endpoint of the study on day 8. This single endpoint biodistribution data serves a quite different function than the dynamic SPECT data. It can inform in which other organs a radiolabeled drug accumulates, especially if it is at very low activities that are not apparent by SPECT. This can be very important for the investigation of long-term effects, side effects and toxicities.
Activities measured by SPECT analysis are overall similar to the biodistribution results (see next paragraph). With both methods, the higher MW HPGs showed higher overall tumor uptake. The highest tumor activity with the clearest inter-MW distinction was observed on day 4 and then remained almost constant until day 8. There is no difference between tumor accumulation on day 4 for the 100, 200, 300 and 500 kDa MW and
Biodistribution
To perform an evaluation of the residence time of the six nanocarriers in the mouse body, the whole body activity was determined on day 8 and compared to the injected dose. The remaining activity (% ID) on day 8 was 17.0, 33.1, 59.3, 72.9, 66.0, 65.3% ID for 25, 50, 100, 200, 300 and 500 kDa groups, respectively. To compare this remaining activity with the tumor activities the numbers were normalized by the body weight to produce % ID per g (Fig. 5, primary axis) . The tumor activities (% ID per g) showed the same trend with 2.3, 3.8, 7.9, 10.4, 8.1 and 7.1% ID per g (Fig. 5, secondary axis) as the body activities (% ID per g). Tumor accumulation between the 100, 200, 300 and 500 kDa groups was not signicantly different (single factor ANOVA, a ¼ 0.05). The tumor concentrations (Fig. 5, blue curve) are above the body concentrations, which points to tumor accumulation. Furthermore, the tumor-to-body ratio (dotted line) is constant at $3 across the different groups, which points to a molecular-weight independent constant percentage in the tumor.
A complete biodistribution for all relevant organs on day 8 is shown in Fig. 6 . Overall, the organs with the highest DFO-HPG concentration were spleen, liver, tumor and bladder. High activities in spleen and liver were expected as pinocytosis may occur here through macrophages and Kupffer cells. We have previously shown that HPGs do not activate complement and have minimal interaction with blood proteins. 32 Reasons for the increased uptake in spleen and liver can be further investigated. A reason for the very high spleen concentration is that these immunocompromised Rag2m mice have a very small spleen, which at $0.015 g is about 10Â smaller than normal.
Overall, the study of the distribution of multifunctional nanomaterials can be challenging. However, these processes take place over many days, and DFO complexes thus seem to be similarly stable as NOTA (a different Ga chelator) complexes where no in vivo degradation has been reported. If there is no metal bound to the DFO, it has been shown that degradation is quite rapid, 48 however, such un-labeled molecules would be invisible in SPECT and do not have to be accounted for here. The 67 Ga-DFO part is not the only possible point where degradation can take place in a multifunctional imaging agent. The HPG itself has been reported to be non-biodegradable. There is no hydrolysis or degradation of HPGs in vitro in buffer at pH 5 and 7.4 over up to 30 days.
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As we cannot know precisely how the tested molecules change aer injection, we cannot attribute a certain outcome to an exact polymer size (e.g., "the 500 kDa construct circulates the longest"), but we would rather conclude that constructs that were larger to begin with circulated longer. We are condent that the methods used here can be very valuable to assess distribution in a non-invasive manner and to quickly screen for the distribution and circulation time of particulate systems in vivo. Especially for cancer therapy, quantifying the tumor accumulation by in vivo imaging, SPECT/CT (or PET/CT, depending on the available radioisotopes) is a valuable tool to determine the time point when tumor activity reaches its maximum, as well as describing the active dose of a drug that reaches the target area.
Pharmacokinetic parameters
The plasma half-live and whole-body half-life of different 67 Ga-DFO-HPG nanocarriers calculated from inside the heart and whole body activities measured by quantitative SPECT data are shown in Fig. 7 . The sampling points were strategically distributed over 8 days to capture the expected residence time of the polymers in the mice. While the blood circulation half-life of nanomaterials is usually determined using blood sampling, we present an easy method that uses qSPECT inside the heart (t 1/2Heart ). By placing the VOIs (r ¼ 1.5 mm) inside the heart, the main activity detected is from blood inside the ventricle and excludes the activity of the heart muscle itself. Furthermore we calculated an additional half-life that indicates how long the nanomaterial stays in the body regardless if circulating or not (whole body residence time). We obtained this value using the qSPECT of the whole mouse body (t 1/2WB ). These two halflives for all tested model nanocarriers are summarized in Table 4 . As shown here, the heart activity vs. time data serves as a sufficient estimator for the macromolecules' blood halflife. In fact, our estimates match the previously reported half-lives for DFO-HPGs closely. A 75 kDa and 637 kDa Fig. 7 The whole body activities (A) and activities inside the heart (B) (n ¼ 4) (average AE SD) from quantitative SPECT data from Rag2m mice bearing subcutaneous (SQ) tumors injected with 67 Ga-DFO-HPG used for pharmacokinetics (PK) analysis.
construct had reported half-lives of 16 and 44 hours, 35 whereas our 50, 100 and 500 kDa constructs have half-lives of 17, 38 and 48 hours, respectively.
Limitations of the study
This study explores the capabilities and methodology of quantitative SPECT analysis, presents several interpretations of measured SUVs and offers an easy method to extract pharmacokinetic parameters non-invasively. Furthermore, it attempts a comparison with the standard invasive technique for the study of nanomaterial distribution (biodistribution technique). We acknowledge that this study has some limitations. The authors carefully selected nanomaterials of certain size distributions, which are narrow and have PDIs close to 1, but are certainly not perfect. Furthermore, we used one tumor model and did not compare different tumor models for these techniques. However, our methods, ndings and interpretations can be easily applied and compared with other tumor models and different nanomaterials in the future, something that is beyond the scope of this manuscript.
Conclusions
Our study explores the advantages of quantitative SPECT/CT imaging to determine the organ and tumor distribution of radiolabeled nanocarriers. Compared to the classic biodistribution methodology, SPECT/CT does not require sacricing the experimental animal to dynamically determine organ activities and allows the researcher to determine the amount of circulating radiolabeled nanocarrier at any time. Comparing the tumor-to-blood ratio dynamically can give the researcher an interesting insight into how blood and tumor concentrations change over time and at what time an equilibrium is reached. The time of equilibrium is size-dependent and increases with molecular weight. The VOI analysis employed here is a fast and efficient way to determine pharmacokinetic parameters such as the blood half-life in mice without blood sampling. Monitoring the activity concentration inside the heart and other organs with multiple spherical VOIs placed inside the organs and tumor is an efficient and reproducible way to determine average organ and tumor activities or SUVS.
An interesting trend was observed in the biodistribution data and the SPECT quantications on day 8. On day 8, a certain amount of nanocarrier is still remaining in the body. If this remaining activity is taken into account, the tumor-to-body ratio is constant at around 3 ( Fig. 5) , so that one could interpret that the tumor might not take up nanocarriers preferentially based on size. This nding might have no direct therapeutic impact, since for an effective treatment, the total tumor accumulation and not the ratio is of main importance. Larger MW nanocarriers can circulate longer, 51 and it has also been conrmed in this study that this will lead to higher total nanocarrier amounts in the tumor (e.g., 2.3% ID per g for the 25 kDa vs. 10.4% ID per g for the visually best-performing 200 kDa group) (Fig. 5) . However, one can hypothesize that complex mixtures of nanomaterials could have an interesting future in an attempt to tailor and maximize tumor accumulation.
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